Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
01 nov. 2018 16h05 HE
|
Geron Corporation
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology...
Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
01 nov. 2018 10h50 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
01 nov. 2018 06h20 HE
|
Geron Corporation
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron...
Geron Announces Discontinuation of Imetelstat Collaboration by Janssen
27 sept. 2018 06h00 HE
|
Geron Corporation
Geron regains global rights to imetelstat programHighlights reported for IMerge and IMbarkGeron plans to initiate the Phase 3 portion of IMergeConference call scheduled for 8:00 a.m. ET today MENLO...
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
12 déc. 2017 07h30 HE
|
Geron Corporation
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented Analyst and Investor Meeting and Webcast at 8:30 a.m. ET on December 19, 2017 MENLO PARK, Calif., Dec. ...
Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
20 nov. 2017 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3...
Geron Announces Presentations at American Society of Hematology Annual Meeting
01 nov. 2017 09h05 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the telomerase inhibitor imetelstat have been accepted for...
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
06 déc. 2016 16h01 HE
|
Geron Corporation
MENLO PARK, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced four presentations of exploratory preclinical and clinical data related to the imetelstat...
Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
02 déc. 2016 08h00 HE
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present...
CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-Thalassemia
21 nov. 2016 08h00 HE
|
CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...